According to the research conducted by the University College London (UCL), the coronavirus antibody levels reportedly start to witness a decline as early as six weeks after complete vaccination with Pfizer and AstraZeneca jabs.
Moreover, these can reduce by more than half over 10 weeks. Therefore, the need for booster doses may be pertinent in the future.
Meanwhile, the research published in The Lancet is based on data from over 600 people. The study further informs that the antibody levels are substantially higher following two doses of the Pfizer or AstraZeneca vaccine, manufactured in India as Covishield by Serum Institute of India (SII). Moreover, the antibodies are also much higher in those who have received both jabs after becoming infected with COVID-19.
On the other hand, Pfizer is reportedly in the midst of seeking its US authorization for its third vaccine for COVID-19. It claimed on Thursday that another shot within 12 months will augment immunity and keep at bay the latest mutants arising.
According to certain research in several countries, Pfizer amongst the many other utilized vaccines offers a high level of immunity against the delta variant. This new variant has posed a cause of concern for a large number of cases not only in the USA but also around the world. In cases of the majority of the vaccines, two jabs become integral to develop antibodies. Whilst some countries have been undertaking their vaccine campaigns on a war footing, some are still fumbling to get their hands on the doses.
Share
Tweet
